<DOC>
	<DOC>NCT00282230</DOC>
	<brief_summary>A study to evaluate the safety and efficacy of Prograf/FK778 in de novo kidney transplant patients</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patient is a recipient of a primary or retransplanted cadaveric or nonHLAidentical living donor kidney. Patient must receive first oral dose of randomized study drug within 48 hours of transplant procedure. Patient has received or is receiving an organ transplant other than kidney Patient has received a kidney transplant from a cadaveric donor &gt;= 60 years of age.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Malononitrilamide</keyword>
	<keyword>immunosuppression</keyword>
	<keyword>treatment efficacy</keyword>
	<keyword>treatment outcome</keyword>
</DOC>